144 related articles for article (PubMed ID: 20116344)
21. Sequential evaluation of prostate edema after permanent seed prostate brachytherapy using CT-MRI fusion.
Taussky D; Austen L; Toi A; Yeung I; Williams T; Pearson S; McLean M; Pond G; Crook J
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):974-80. PubMed ID: 15989997
[TBL] [Abstract][Full Text] [Related]
22. Rectal-wall dose dependence on postplan timing after permanent-seed prostate brachytherapy.
Taussky D; Yeung I; Williams T; Pearson S; McLean M; Pond G; Crook J
Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):358-63. PubMed ID: 16563654
[TBL] [Abstract][Full Text] [Related]
23. Randomized trial of high- and low-source strength (125)I prostate seed implants: In regard to Narayana et al. (Int J Radiat Oncol Biol Phys 2005;61:44-51).
Moerland MA; Battermann JJ
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):941-2. PubMed ID: 15936582
[No Abstract] [Full Text] [Related]
24. Recommendations for permanent prostate brachytherapy with (131)Cs: a consensus report from the Cesium Advisory Group.
Bice WS; Prestidge BR; Kurtzman SM; Beriwal S; Moran BJ; Patel RR; Rivard MJ;
Brachytherapy; 2008; 7(4):290-6. PubMed ID: 18782682
[TBL] [Abstract][Full Text] [Related]
25. Intraoperative conformal optimization for transperineal prostate implantation using magnetic resonance spectroscopic imaging.
Zelefsky MJ; Cohen G; Zakian KL; Dyke J; Koutcher JA; Hricak H; Schwartz L; Zaider M
Cancer J; 2000; 6(4):249-55. PubMed ID: 11038145
[TBL] [Abstract][Full Text] [Related]
26. Prostate-specific antigen bounce after permanent iodine-125 prostate brachytherapy--an Australian analysis.
Zwahlen DR; Smith R; Andrianopoulos N; Matheson B; Royce P; Millar JL
Int J Radiat Oncol Biol Phys; 2011 Jan; 79(1):179-87. PubMed ID: 20378267
[TBL] [Abstract][Full Text] [Related]
27. The effect of the radial function on I-125 seeds used for permanent prostate implantation.
Pickett B; Pouliot J
Med Dosim; 2004; 29(3):204-9. PubMed ID: 15324917
[TBL] [Abstract][Full Text] [Related]
28. Three-dimensional real-time magnetic resonance-guided interstitial prostate brachytherapy optimizes radiation dose distribution resulting in a favorable acute side effect profile in patients with clinically localized prostate cancer.
Hurwitz MD; Cormack R; Tempany CM; Kumar S; D'Amico AV
Tech Urol; 2000 Jun; 6(2):89-94. PubMed ID: 10798806
[TBL] [Abstract][Full Text] [Related]
29. Influence of prophylactic dexamethasone on edema following prostate brachytherapy.
Merrick GS; Butler WM; Dorsey AT; Lief JH; Totterd ; Coram RJ
Tech Urol; 2000 Jun; 6(2):117-22. PubMed ID: 10798812
[TBL] [Abstract][Full Text] [Related]
30. Randomized trial of high- and low-source strength (125)I prostate seed implants.
Narayana V; Troyer S; Evans V; Winfield RJ; Roberson PL; McLaughlin PW
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):44-51. PubMed ID: 15629592
[TBL] [Abstract][Full Text] [Related]
31. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
Mabjeesh NJ; Chen J; Stenger A; Matzkin H
Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
[TBL] [Abstract][Full Text] [Related]
32. Urethral stone formation after permanent radioactive seed implant for prostate cancer.
Steinmetz R; Barrett W
Am J Clin Oncol; 2006 Aug; 29(4):424-5. PubMed ID: 16891876
[No Abstract] [Full Text] [Related]
33. Variations in health-related quality of life in Japanese men who underwent iodine-125 permanent brachytherapy for localized prostate cancer.
Tanaka N; Fujimoto K; Asakawa I; Hirayama A; Yoneda T; Yoshida K; Hirao Y; Hasegawa M; Konishi N
Brachytherapy; 2010; 9(4):300-6. PubMed ID: 20708440
[TBL] [Abstract][Full Text] [Related]
34. Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy?
Potters L; Calugaru E; Jassal A; Presser J
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1014-9. PubMed ID: 16682144
[TBL] [Abstract][Full Text] [Related]
35. Editorial comment.
Lee WR
Urology; 2010 Jun; 75(6):1416-7; author reply 1417. PubMed ID: 20513503
[No Abstract] [Full Text] [Related]
36. Technical acquisition and dosimetric assessment of iodine-125 permanent brachytherapy in localized prostate cancer: our first series of 100 patients.
Tanaka N; Asakawa I; Kondo H; Tanaka M; Fujimoto K; Hasegawa M; Konishi N; Hirao Y
Int J Urol; 2009 Jan; 16(1):70-4. PubMed ID: 19120529
[TBL] [Abstract][Full Text] [Related]
37. Biologically effective dose for permanent prostate brachytherapy taking into account postimplant edema.
Van Gellekom MP; Moerland MA; Kal HB; Battermann JJ
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):422-33. PubMed ID: 12023147
[TBL] [Abstract][Full Text] [Related]
38. Point: the relationship between postimplant dose metrics and biochemical no evidence of disease following low dose rate prostate brachytherapy: is there an elephant in the room?
Morris WJ; Halperin R; Spadinger I
Brachytherapy; 2010; 9(4):289-92; discussion 297-8. PubMed ID: 20739226
[No Abstract] [Full Text] [Related]
39. Effect of edema on the post-implant dosimetry of an I-125 prostate implant: a case study.
Waterman FM; Yue N; Reisinger S; Dicker A; Corn BW
Int J Radiat Oncol Biol Phys; 1997 May; 38(2):335-9. PubMed ID: 9226320
[TBL] [Abstract][Full Text] [Related]
40. Anisotropy characterization of I-125 seed with attached encapsulated cobalt chloride complex contrast agent markers for MRI-based prostate brachytherapy.
Frank SJ; Tailor RC; Kudchadker RJ; Martirosyan KS; Stafford RJ; Elliott AM; Swanson DA; Sing D; Choi J; Mourtada F; Ibbott GS
Med Dosim; 2011; 36(2):200-5. PubMed ID: 20537886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
